BMC microbiology · 2026
Efficacy of regimens targeting Mycobacterium abscessus in vitro and in vivo.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Zimo, Ye Yangxue, Zhang Weiyan, Wang Bin, Chen Xiaoyou, Lu Yu
Аннотация
BACKGROUND: M. abscessus (Mabs) is one of the principal pathogenic strains among nontuberculous mycobacterial. Mabs infections pose a significant global public health challenge, leading to substantial morbidity and mortality. However, a standard treatment regimen has not yet been established. The goal of this study was to provide clear insights into constructing regimens.
METHODS: We evaluated the efficacy of 7 clinically available drugs against Mabs under various environments through microplate alamar blue assay (MABA), biofilm assays, Wayne model and nutrient-starvation model. The checkerboard assay was employed to assess drug-drug interactions. Finally, we assessed the efficacy, degree of organ damage, and prevalence of resistant strains associated with different triple-drug combinations in a BALB/c mouse model.
RESULTS: Bedaquiline (BDQ) was active against replicating and nonreplicating planktonic bacteria. Moxifloxacin (MFX) was potent in preventing biofilm formation and inhibiting the viability of biofilm-resident bacteria. ABM (Azithromycin-Bedaquiline-Moxifloxacin) and CBM (Clofazimine-Bedaquiline-Moxifloxacin) combinations were effective in bacillary load reduction and organ injury alleviation in BALB/c mouse model.
CONCLUSIONS: ABM and CBM regimens show great promise against Mabs in vivo. We strongly recommend carrying out additional clinical trials to explore their efficacy.
METHODS: We evaluated the efficacy of 7 clinically available drugs against Mabs under various environments through microplate alamar blue assay (MABA), biofilm assays, Wayne model and nutrient-starvation model. The checkerboard assay was employed to assess drug-drug interactions. Finally, we assessed the efficacy, degree of organ damage, and prevalence of resistant strains associated with different triple-drug combinations in a BALB/c mouse model.
RESULTS: Bedaquiline (BDQ) was active against replicating and nonreplicating planktonic bacteria. Moxifloxacin (MFX) was potent in preventing biofilm formation and inhibiting the viability of biofilm-resident bacteria. ABM (Azithromycin-Bedaquiline-Moxifloxacin) and CBM (Clofazimine-Bedaquiline-Moxifloxacin) combinations were effective in bacillary load reduction and organ injury alleviation in BALB/c mouse model.
CONCLUSIONS: ABM and CBM regimens show great promise against Mabs in vivo. We strongly recommend carrying out additional clinical trials to explore their efficacy.